Jasper Therapeutics (NASDAQ:JSPR) Announces Earnings Results

Jasper Therapeutics (NASDAQ:JSPR) released its earnings results on Monday. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.79) by $0.47, reports.

Jasper Therapeutics Stock Down 2.6%

NASDAQ JSPR opened at $0.88 on Wednesday. The stock has a market capitalization of $24.52 million, a PE ratio of -0.19 and a beta of 3.08. Jasper Therapeutics has a 12-month low of $0.81 and a 12-month high of $7.19. The company has a 50 day moving average price of $1.32 and a two-hundred day moving average price of $1.76.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Jasper Therapeutics in a report on Thursday, January 22nd. Rodman & Renshaw initiated coverage on Jasper Therapeutics in a report on Tuesday, January 13th. They set a “buy” rating and a $17.00 price objective for the company. Finally, UBS Group began coverage on Jasper Therapeutics in a research report on Monday, March 23rd. They set a “neutral” rating for the company. Six equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $19.88.

Institutional Investors Weigh In On Jasper Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Quadrature Capital Ltd acquired a new position in Jasper Therapeutics during the fourth quarter worth $123,000. Millennium Management LLC boosted its stake in shares of Jasper Therapeutics by 194.2% during the 4th quarter. Millennium Management LLC now owns 1,073,783 shares of the company’s stock worth $1,965,000 after acquiring an additional 708,844 shares in the last quarter. Engineers Gate Manager LP bought a new stake in shares of Jasper Therapeutics during the 4th quarter worth about $26,000. Boothbay Fund Management LLC increased its holdings in shares of Jasper Therapeutics by 79.4% during the 4th quarter. Boothbay Fund Management LLC now owns 793,954 shares of the company’s stock valued at $1,453,000 after acquiring an additional 351,312 shares during the last quarter. Finally, ADAR1 Capital Management LLC acquired a new position in shares of Jasper Therapeutics during the 4th quarter valued at about $256,000. Institutional investors and hedge funds own 79.85% of the company’s stock.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.